Antiandrogens in the Treatment of Prostate Cancer

European Urology

Volumn 51, Issue 2, 2007, Pages 306-314

  Wirth, Manfred P ^a   Hakenberg, Oliver W ^a   Froehner, Michael ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Antiandrogens; Bicalutamide; Cyproterone acetate; Flutamide; Hormonal treatment; Nilutamide; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GOSERELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMOXIFEN;

ADVANCED CANCER; ALCOHOL INTOLERANCE; ANAPHYLAXIS; BEAM THERAPY; BLEEDING; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE EXACERBATION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EARLY CANCER; EMBOLISM; GLEASON SCORE; GYNECOMASTIA; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPOTENSION; IMPOTENCE; INTERSTITIAL PNEUMONIA; LIBIDO DISORDER; LIPID STORAGE; LIVER TOXICITY; LUNG EMBOLISM; MASTALGIA; METASTASIS POTENTIAL; MICROMETASTASIS; MONOTHERAPY; NAUSEA; ORCHIECTOMY; OSTEOPOROSIS; OVERALL SURVIVAL; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RETINA BLOOD VESSEL OCCLUSION; REVIEW; SEXUAL BEHAVIOR; SHOCK; SIDE EFFECT; SUPERFICIAL THROMBOPHLEBITIS; SURVIVAL RATE; SURVIVAL TIME; SYNCOPE; TACHYCARDIA; TESTOSTERONE BLOOD LEVEL; THROMBOSIS; TREATMENT INDICATION; VASCULAR HEADACHE; VISUAL DISORDER; WITHDRAWAL SYNDROME;

ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 33845580082     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.08.043     Document Type: Review

References (43)

1. Walsh P.C., deWeese T.L., and Eisenberger M.A. A structured debate: immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment. J Urol 166 (2001) 508-515
2. Huggins C., and Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
3. Ryan C.J., and Small E.J. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol 23 (2005) 8225-8231
4. Lam J.S., Leppert J.T., Vemulapalli S.N., Shvarts O., and Belldegrun A.S. Secondary hormonal therapy for advanced prostate cancer. J Urol 175 (2006) 27-34
5. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
6. Routh J.C., and Leibovich B.C. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc 80 (2005) 899-907
7. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 91 (2003) 455-461
8. Lefort M., Curiel M.D., Carrascal M.T., Mendez-Davila C., and De la Piedra C. Comparative effects of bicalutamide versus orchidectomy on bone mineral density, bone remodelling and bone biomechanics in healthy rats. Urol Int 74 (2005) 301-307
9. Smith M.R., Goode M., Zietman A.L., McGovern F.J., Lee H., and Finkelstein J.S. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22 (2004) 2546-2553
10. Sieber P.R., Keiller D.L., Kahnoski R.J., Gallo J., and McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 171 (2004) 2272-2276
11. Wirth M., Tyrrell C., Delaere K., Sanchez-Chapado M., Ramon J., Wallace D.M., et al. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis 8 (2005) 194-200
12. Abrahamsson P.A., Anderson J., Boccon-Gibod L., Schulman C., Studer U.E., and Wirth M. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer. Eur Urol 48 (2005) 900-905
13. Tyrrell C.J., Payne H., See W.A., McLeod D.G., Wirth M.P., Iversen P., et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 76 (2005) 4-10
14. Perdona S., Autorino R., De Placido S., D'Armiento M., Gallo A., Damiano R., et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 6 (2005) 295-300
15. Boccardo F., Rubagotti A., Battaglia M., Di Tonno P., Selvaggi F.P., Conti G., et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 23 (2005) 808-815
16. Van Poppel H., Tyrrell C.J., Haustermans K., Van Cangh P., Keuppens F., Colombeau P., et al. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol 47 (2005) 587-592
17. Encyclopedia of cancer. Encyclopedia of Cancer: Antiandrogens: eNotes.com LLC (http://www.enotes.com/cancer-encyclopedia), 2006.
18. McLeod D.G., Iversen P., See W.A., Morris T., Armstrong J., Wirth M.P., et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97 (2006) 247-254
19. Iversen P., Tyrrell C.J., Kaisary A.V., Anderson J.B., van Poppel H., Tammela T.L.J., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 164 (2000) 1579-1582
20. Iversen P. Bicalutamide monotherapy for early state prostate cancer. J Urol 170 (2003) S48-S54
21. Boccardo F., Barichello M., Battaglia M., Carmignani G., Comeri G., Ferraris V., et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 42 (2002) 481-490
22. Tyrrell C.J., Kaisary A.V., Iversen P., Anderson J.B., Baert L., Tammela T., et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33 (1998) 447-456
23. Aus G., Abbou C.C., Heidenreich A., Schmid H.P., van Poppel H., Wolff J., and Zattoni F. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
24. Kaisary A.V., Iversen P., Tyrrell C.J., Carroll K., and Morris T. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?. Prostate Cancer Prostatic Dis 4 (1999) 196-203
25. Schröder F.H., Whelan P., de Reijke T.M., Kurth K.H., Pavone-Macaluso M., Mattelaer J., et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Eur Urol 45 (2004) 457-464
26. Thorpe S.C., Azmatullah S., Fellows G.J., Gingell J.C., and O'Boyle P.J. A prospective randomized study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 29 (1996) 47-54
27. Loblaw D.A., Mendelson D.S., Talcott J.A., Virgo K.S., Somerfield M.R., Ben-Josef E., et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22 (2004) 2927-2941
28. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238-244
29. Oh W.K., Manola J., Bittmann L., Brufsky A., Kaplan I.D., Smith M.R., et al. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology 62 (2003) 99-104
30. Wirth M., Tyrrell C., Wallace M., Delaere K.P., Sanchez-Chapado M., Ramon J., et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 58 (2001) 146-151
31. Wirth M.P., See W.A., McLeod D.G., Iversen P., Morris T., Carroll K., et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172 (2004) 1865-1870
32. Samson D.J., Seidenfeld J., Schmitt B., Hasselblad V., Albertsen P.C., Bennett C.L., et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer Res 95 (2002) 361-376
33. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet Oncol 355 (2000) 1491-1498
34. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
35. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Engl J Med 341 (1999) 1781-1788
36. Wirth M.P., Weissbach L., Marx F.J., Heckl W., Jellinghaus W., Riedmiller H., et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 45 (2004) 267-270
37. Pilepich M.V., Winter K., John M.J., Mesic J.B., Sause W., Rubin P., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
38. Henderson A., Langley S.E., and Laing R.W. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol (R Coll Radiol) 15 (2003) 316-317
39. Kelly W.K., and Scher H.I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 149 (1993) 607-609
40. Kojima S., Suzuki H., Akakura K., Shimbo M., Ichikawa T., and Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171 (2004) 679-683
41. Yoshida T., Kinoshita H., Segawa T., Nakamura E., Inoue T., Shimizu Y., et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 65 (2005) 9611-9616
42. Nakabayashi M., Regan M.M., Lifsey D., Kantoff P.W., Taplin M.E., Sartor O., et al. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int 96 (2005) 783-786
43. Tan A., Tuckey J., and Rice M. Orchidectomy following failure of antiandrogen monotherapy in patients with metastatic prostate cancer. Eur Urol 40 (2001) 130-133